HYMPAVZI is the first and only approved anti-tissue factor pathway inhibitor in the US for haemophilia A or B treatment.

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge from an activist investor.

Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and ...

Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain ...

Pfizer announced on Friday that the U.S. Food and Drug Administration has granted approval for its once-weekly injection ...

Pfizer’s Hympavzi receives US FDA approval to treat adults and adolescents with haemophilia A or B without inhibitors: New York Monday, October 14, 2024, 18:00 Hrs [IST] Pfizer ...

The FDA has approved a new preventive treatment for people with certain types of hemophilia that can reduce bleeding episodes, sometimes down to just a few per year.

TSMC is planning new factories in Europe focused on AI chips after starting construction on its first plant in Dresden, ...

Daiichi Sankyo and AstraZeneca's ENHERTU has been conditionally approved by China's NMPA for a specific type of NSCLC.

Inventiva will gain a new chairman following the deal as it presses ahead with a Phase III trial for its lead asset.

One doctor spoke out warning that women may be getting misdiagnosed with a common condition when they may actually be ...

Cancer Research UK hailed the shift as the biggest improvement in cervical cancer treatment in more than 20 years ...